MetaCap

Biomea Fusion (BMEA) vs Elicio Therapeutics (ELTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biomea Fusion (BMEA) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 41.5% versus a loss of 82.8%. Over five years, BMEA leads with a -95.2% price change compared with -96.1% for ELTX. Biomea Fusion is the larger company by market cap ($41.7 million vs $41.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMEA-41.51%ELTX-82.84%
+135%+21%-94%
Nov 21, 20251 yearNov 20, 2026
BMEA-94.67%ELTX-96.46%
+298%+91%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMEA versus ELTX key metrics
MetricBMEAELTX
Share price$0.5744$1.45
Market cap$41.75M$41.05M
1-day change-2.38%-3.33%
YTD return-53.68%-81.78%
1-year return-41.51%-82.84%
5-year return-95.21%-96.13%
EPS (TTM)$-0.10$-1.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-61.80M$-39.57M
52-week high$2.24$16.00
52-week low$0.45$1.25
Distance from 52-week high-74.32%-90.94%
Analyst consensusbuystrong_buy
Avg. price target upside+1118.66%+842.76%
Average volume2.22M324.71K
Shares outstanding72.68M28.31M
Employees3733
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BMEA has outperformed ELTX by 41.3 percentage points over the past year.

About Biomea Fusion

BMEA stock →

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

BMEA vs ELTX FAQ

Which is bigger, Biomea Fusion or Elicio Therapeutics?

Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $41.05M for Elicio Therapeutics (ELTX).

Which stock has performed better over the past year, BMEA or ELTX?

BMEA returned -41.51% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.

Are Biomea Fusion and Elicio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons